COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES

被引：0
|
作者：
Aggarwal, S. [1 ]
Topaloglu, O. [1 ]
Kumar, S. [2 ]
机构：
[1] NOVEL Hlth Strategies, Chevy Chase, MD USA
[2] Inst Global Policy, Washington, DC USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.187
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN110
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis
    Habibi, Mohammad Amin
    Mirjani, Mohammad Sina
    Ahmadvand, Muhammad Hussain
    Delbari, Pouria
    Eftekhar, Mohammad Shahir
    Ghazizadeh, Yalda
    Ghezel, Mohammad Amin
    Rad, Romina Hamidi
    Vakili, Kimia Ghazi
    Lotfi, Sohrab
    Minaee, Poriya
    Eazi, Seyedmohammad
    Mehrizi, Mohammad Ali Abouei
    Ahmadpour, Sajjad
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [22] A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors
    Martorana, F.
    Colombo, I.
    Treglia, G.
    Gillessen, S.
    Stathis, A.
    CANCER TREATMENT REVIEWS, 2021, 101
  • [23] Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
    Francesco Spagnolo
    Andrea Boutros
    Federica Cecchi
    Elena Croce
    Enrica Teresa Tanda
    Paola Queirolo
    BMC Cancer, 21
  • [24] Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
    Spagnolo, Francesco
    Boutros, Andrea
    Cecchi, Federica
    Croce, Elena
    Tanda, Enrica Teresa
    Queirolo, Paola
    BMC CANCER, 2021, 21 (01)
  • [25] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [26] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Gang Chen
    Alexander C. Huang
    Wei Zhang
    Gao Zhang
    Min Wu
    Wei Xu
    Zili Yu
    Jiegang Yang
    Beike Wang
    Honghong Sun
    Houfu Xia
    Qiwen Man
    Wenqun Zhong
    Leonardo F. Antelo
    Bin Wu
    Xuepeng Xiong
    Xiaoming Liu
    Lei Guan
    Ting Li
    Shujing Liu
    Ruifeng Yang
    Youtao Lu
    Liyun Dong
    Suzanne McGettigan
    Rajasekharan Somasundaram
    Ravi Radhakrishnan
    Gordon Mills
    Yiling Lu
    Junhyong Kim
    Youhai H. Chen
    Haidong Dong
    Yifang Zhao
    Giorgos C. Karakousis
    Tara C. Mitchell
    Lynn M. Schuchter
    Meenhard Herlyn
    E. John Wherry
    Xiaowei Xu
    Wei Guo
    Nature, 2018, 560 : 382 - 386
  • [27] Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
    de Jong, Florus C.
    Rutten, Vera C.
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [28] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
    Katy K. Tsai
    Adil I. Daud
    Drugs, 2015, 75 : 563 - 575
  • [29] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Kirienko, Margarita
    Sollini, Martina
    Chiti, Arturo
    CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (06) : 417 - 427
  • [30] Association Between Anti-PD-1/PD-L1 Drugs and Hearing Impairment
    Morel, Aurore
    Moiny, Maxime
    Azzouz, Brahim
    DRUG SAFETY, 2024, 47 (12) : 1407 - 1408
12345